Renaissance Technologies’s Zynerba Pharmaceuticals, Inc ZYNE Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2023
Q4 | – | Sell |
-605,700
| Closed | -$772K | – | 4293 |
|
|
2023
Q3 | $772K | Sell |
605,700
-84,013
| -12% | -$73.4K | ﹤0.01% | 2468 |
|
|
2023
Q2 | $225K | Buy |
689,713
+120,013
| +21% | +$43K | ﹤0.01% | 3254 |
|
|
2023
Q1 | $245K | Sell |
569,700
-270,800
| -32% | -$143K | ﹤0.01% | 3194 |
|
|
2022
Q4 | $445K | Sell |
840,500
-269,535
| -24% | -$171K | ﹤0.01% | 3013 |
|
|
2022
Q3 | $813K | Buy |
1,110,035
+373,435
| +51% | +$424K | ﹤0.01% | 2623 |
|
|
2022
Q2 | $840K | Buy |
736,600
+408,200
| +124% | +$520K | ﹤0.01% | 2826 |
|
|
2022
Q1 | $673K | Sell |
328,400
-59,985
| -15% | -$143K | ﹤0.01% | 2992 |
|
|
2021
Q4 | $1.12M | Buy |
388,385
+31,403
| +9% | +$116K | ﹤0.01% | 2561 |
|
|
2021
Q3 | $1.51M | Buy |
+356,982
| New | +$1.59M | ﹤0.01% | 2303 |
|
|
2021
Q1 | – | Sell |
-144,000
| Closed | -$475K | – | 3822 |
|
|
2020
Q4 | $475K | Buy |
144,000
+125,400
| +674% | +$476K | ﹤0.01% | 2841 |
|
|
2020
Q3 | $62K | Buy |
+18,600
| New | +$68.3K | ﹤0.01% | 3258 |
|
|
2019
Q1 | – | Sell |
-184,300
| Closed | -$547K | – | 3764 |
|
|
2018
Q4 | $547K | Buy |
+184,300
| New | +$1.01M | ﹤0.01% | 2829 |
|
Renaissance Technologies's ZYNE Position: Q4 2023 in Review
Renaissance Technologies sold out of Zynerba Pharmaceuticals, Inc (ZYNE) in Q4 2023, closing a stake of 605,700 shares — an estimated $772K sold.
Renaissance Technologies first reported a position in ZYNE in Q4 2018 and held it in 12 quarters. The position peaked at $1.51M in Q3 2021. 0 funds tracked by Wall St. Rank hold ZYNE as of Q4 2023.
- Renaissance Technologies reported no remaining Zynerba Pharmaceuticals, Inc position as of Q4 2023 after selling out during the quarter.
- Renaissance Technologies sold 605,700 Zynerba Pharmaceuticals, Inc shares in Q4 2023, an estimated $772K.
- Renaissance Technologies first reported a position in Zynerba Pharmaceuticals, Inc in Q4 2018 and held it in 12 quarters.
- Renaissance Technologies's Zynerba Pharmaceuticals, Inc position peaked at $1.51M in Q3 2021.
- 0 funds tracked by Wall St. Rank held Zynerba Pharmaceuticals, Inc as of Q4 2023.
Based on Renaissance Technologies's 13F filing for Q4 2023, filed 13 Feb 2024.